Last updated: 2026-09-16 13:20:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Sarepta Therapeutics,, Inc. (SRPT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $20.66, with a market capitalisation of $2.21B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $14.68 to $25.32. This page covers its latest market performance, valuation, price trends and company information.
$2.21B | |
$20.45 | |
$181.83 | |
$3.30 | |
$20.72 | |
93.00 | |
3.41M | |
-- | |
$25.32 | |
$14.68 | |
-- | |
-- |
Sarepta Therapeutics,, Inc. (SRPT) is trading at $20.66 in pre-market trading as of 2026-09-16 11:47:00, down 0.29% ($0.06) from the previous close of $20.72
Pre-market trading shows how investors are pricing SRPT before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Sarepta Therapeutics,, Inc. (SRPT) moved from $22.50 to $20.66, representing a decline of 8.18% ($1.84).
The stock traded between $19.51 and $23.22 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 3.16 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 56.2%
SRPT is currently trading at $20.66, placing it 56.2% of the way from its 52-week low of $14.68 to its 52-week high of $25.32. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 835 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Sarepta Therapeutics,, Inc. (SRPT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.